2.48
price up icon5.08%   0.12
after-market Handel nachbörslich: 2.47 -0.010 -0.40%
loading
Schlusskurs vom Vortag:
$2.36
Offen:
$2.35
24-Stunden-Volumen:
780.46K
Relative Volume:
0.17
Marktkapitalisierung:
$425.37M
Einnahmen:
$101.21M
Nettoeinkommen (Verlust:
$-569.00K
KGV:
-124.00
EPS:
-0.02
Netto-Cashflow:
$-56.88M
1W Leistung:
+12.22%
1M Leistung:
-1.20%
6M Leistung:
+133.96%
1J Leistung:
+87.88%
1-Tages-Spanne:
Value
$2.335
$2.505
1-Wochen-Bereich:
Value
$2.15
$2.505
52-Wochen-Spanne:
Value
$0.40
$3.095

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
Firmenname
Cytomx Therapeutics Inc
Name
Telefon
650.515.3185
Name
Adresse
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
121
Name
Twitter
@cytomxinc
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
CTMX's Discussions on Twitter

Vergleichen Sie CTMX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CTMX
Cytomx Therapeutics Inc
2.48 425.37M 101.21M -569.00K -56.88M -0.02
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-15 Hochstufung H.C. Wainwright Neutral → Buy
2025-04-14 Fortgesetzt Piper Sandler Overweight
2024-05-28 Hochstufung Piper Sandler Neutral → Overweight
2024-05-09 Hochstufung Wedbush Neutral → Outperform
2024-05-06 Hochstufung Jefferies Hold → Buy
2024-04-22 Hochstufung JP Morgan Underweight → Neutral
2022-11-14 Herabstufung BMO Capital Markets Outperform → Market Perform
2022-07-07 Herabstufung Jefferies Buy → Hold
2022-07-07 Herabstufung Mizuho Buy → Neutral
2022-07-07 Herabstufung Piper Sandler Overweight → Neutral
2022-07-07 Herabstufung Wedbush Outperform → Neutral
2022-06-24 Eingeleitet BMO Capital Markets Outperform
2022-01-18 Hochstufung Barclays Underweight → Overweight
2021-11-15 Eingeleitet BTIG Research Buy
2021-05-28 Herabstufung Barclays Equal Weight → Underweight
2021-03-29 Eingeleitet JP Morgan Overweight
2021-03-23 Hochstufung Jefferies Hold → Buy
2020-09-22 Herabstufung Guggenheim Buy → Neutral
2020-06-01 Herabstufung Jefferies Buy → Hold
2020-05-14 Bestätigt H.C. Wainwright Buy
2020-03-24 Hochstufung Wedbush Neutral → Outperform
2020-03-04 Eingeleitet Barclays Equal Weight
2019-11-20 Eingeleitet Guggenheim Buy
2019-11-11 Herabstufung Wedbush Outperform → Neutral
2019-06-13 Eingeleitet Mizuho Buy
2019-05-14 Eingeleitet Cantor Fitzgerald Overweight
2019-03-11 Eingeleitet Barclays Overweight
2018-11-26 Eingeleitet Piper Jaffray Overweight
2018-10-15 Eingeleitet Goldman Neutral
2018-09-13 Eingeleitet H.C. Wainwright Buy
2018-06-01 Eingeleitet SunTrust Buy
2018-01-05 Eingeleitet Citigroup Buy
2017-09-08 Eingeleitet Wedbush Outperform
2017-03-27 Eingeleitet H.C. Wainwright Buy
2017-03-02 Eingeleitet Instinet Buy
2017-01-03 Herabstufung Oppenheimer Outperform → Perform
2015-11-02 Eingeleitet Oppenheimer Outperform
Alle ansehen

Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten

pulisher
Jun 17, 2025

CytomX Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView

Jun 17, 2025
pulisher
Jun 17, 2025

CytomX Therapeutics CEO Sells Shares to Meet Tax Obligations - TradingView

Jun 17, 2025
pulisher
Jun 13, 2025

CytomX Therapeutics Approves Key Amendments at Annual Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Stocks in play: Roots Corp. - The Globe and Mail

Jun 13, 2025
pulisher
Jun 11, 2025

Two Sigma Investments LP Cuts Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Cisco Powers AI-Ready Data Centers, From Hyperscale to Enterprise - The Globe and Mail

Jun 10, 2025
pulisher
Jun 09, 2025

GoldMining Announces Closing of Flow-Through Financing and Commences Exploration at Yellowknife Gold Project - The Globe and Mail

Jun 09, 2025
pulisher
Jun 05, 2025

Ballard announces 1.5 MW fuel cell engine order for Sierra Northern Railway - The Globe and Mail

Jun 05, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Grows Stock Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering - MSN

Jun 03, 2025
pulisher
Jun 02, 2025

BMO Lowers Fees on Asset Allocation ETFs to Deliver Greater Value to Investors - The Globe and Mail

Jun 02, 2025
pulisher
May 31, 2025

Millennium Management LLC Grows Stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

May 31, 2025
pulisher
May 31, 2025

CytomX stock soars to 52-week high, hits $2.66 By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

CytomX stock soars to 52-week high, hits $2.66 - Investing.com Australia

May 30, 2025
pulisher
May 29, 2025

CytomX Therapeutics CEO Set for Jefferies Conference: Key Biologics Updates Coming - Stock Titan

May 29, 2025
pulisher
May 29, 2025

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference - The Manila Times

May 29, 2025
pulisher
May 20, 2025

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st

May 20, 2025
pulisher
May 20, 2025

CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga

May 20, 2025
pulisher
May 20, 2025

CytomX Therapeutics (CTMX) Maintains "Buy" Rating with $5.00 Price Target | CTMX Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

CytomX begins trial of new melanoma treatment with Merck therapy By Investing.com - Investing.com South Africa

May 19, 2025
pulisher
May 19, 2025

CytomX begins trial of new melanoma treatment with Merck therapy - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

CytomX (CTMX) Advances Phase 1 Study with CX-801 for Metastatic Melanoma | CTMX Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

CytomX Therapeutics Doses First Patient in Phase 1 Study of CX-801 Combined with KEYTRUDA® for Metastatic Melanoma - Nasdaq

May 19, 2025
pulisher
May 19, 2025

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Clinical Trial Breakthrough: CytomX's New Melanoma Drug Combines With Keytruda in Phase 1 Study - Stock Titan

May 19, 2025
pulisher
May 19, 2025

Equities Analysts Set Expectations for CTMX Q2 Earnings - Defense World

May 19, 2025
pulisher
May 18, 2025

What is HC Wainwright’s Estimate for CTMX FY2026 Earnings? - Defense World

May 18, 2025
pulisher
May 17, 2025

CytomX upgraded at H.C. Wainwright on trial data for cancer drug - MSN

May 17, 2025
pulisher
May 17, 2025

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World

May 17, 2025
pulisher
May 17, 2025

CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by HC Wainwright - Defense World

May 17, 2025
pulisher
May 16, 2025

CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st

May 16, 2025
pulisher
May 15, 2025

H.C. Wainwright raises CytomX stock to buy, target to $5.00 By Investing.com - Investing.com South Africa

May 15, 2025
pulisher
May 15, 2025

CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler - GuruFocus

May 15, 2025
pulisher
May 15, 2025

CytomX Therapeutics (CTMX) Price Target Raised by Piper Sandler | CTMX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

After pivots and layoffs, CytomX Therapeutics smells success, $100 million payoff - The Business Journals

May 15, 2025
pulisher
May 15, 2025

CytomX stock upgraded at H.C. Wainwright (CTMX:NASDAQ) - Seeking Alpha

May 15, 2025
pulisher
May 15, 2025

HC Wainwright & Co. Upgrades CytomX Therapeutics (CTMX) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX - GuruFocus

May 15, 2025
pulisher
May 15, 2025

H.C. Wainwright raises CytomX stock to buy, target to $5.00 - Investing.com

May 15, 2025
pulisher
May 15, 2025

CTMX Stock Rating Upgraded to Buy by HC Wainwright & Co. | CTMX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

HC Wainwright Upgrades CytomX Therapeutics to Buy From Neutral, Price Target is $5 - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

CytomX Therapeutics (CTMX) Price Target Doubled Following Promis - GuruFocus

May 15, 2025
pulisher
May 15, 2025

CTMX Stock Upgraded as New Clinical Data Shows Promise | CTMX St - GuruFocus

May 15, 2025
pulisher
May 15, 2025

CytomX Therapeutics (CTMX) Price Target Doubled Following Promising Trial Results | CTMX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

CTMX Stock Upgraded as New Clinical Data Shows Promise | CTMX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates - MSN

May 15, 2025
pulisher
May 14, 2025

Institutional investors have a lot riding on CytomX Therapeutics, Inc. (NASDAQ:CTMX) with 52% ownership - simplywall.st

May 14, 2025
pulisher
May 14, 2025

CytomX Therapeutics Stock (CTMX): Momentum from Promising Trials - Value The Markets

May 14, 2025
pulisher
May 13, 2025

CytomX Therapeutics Secures $93.4 Million Through Stock Sale - TipRanks

May 13, 2025
pulisher
May 13, 2025

CytomX Therapeutics: Doubling Overnight On Phase 1 Data... Still Bullish? - Seeking Alpha

May 13, 2025
pulisher
May 13, 2025

CytomX (CTMX) Exceeds Revenue Expectations and Advances CRC Drug Development | CTMX Stock News - GuruFocus

May 13, 2025

Finanzdaten der Cytomx Therapeutics Inc-Aktie (CTMX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Cytomx Therapeutics Inc-Aktie (CTMX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Ogden Christopher
Chief Financial Officer
Jun 16 '25
Sale
2.69
10,614
28,540
226,271
Ogden Christopher
Chief Financial Officer
Jun 13 '25
Sale
2.95
1,641
4,841
199,385
BELVIN MARCIA
SVP, Chief Scientific Officer
Jun 13 '25
Option Exercise
0.00
37,500
0
286,136
BELVIN MARCIA
SVP, Chief Scientific Officer
Jun 16 '25
Sale
2.69
13,884
37,334
272,252
McCarthy Sean A.
CEO
Jun 13 '25
Option Exercise
0.00
150,000
0
1,145,195
McCarthy Sean A.
CEO
Jun 16 '25
Sale
2.69
55,511
149,264
1,089,684
McCarthy Sean A.
CEO
Mar 18 '25
Sale
0.60
37,656
22,556
995,195
Ogden Christopher
Chief Financial Officer
Mar 18 '25
Sale
0.60
8,551
5,122
201,026
Chu Yu-Waye
Chief Medical Officer
Mar 18 '25
Sale
0.60
4,025
2,411
135,725
ROWLAND LLOYD A
General Counsel
Mar 18 '25
Sale
0.60
10,203
6,112
120,594
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):